Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Checkpoint inhibitor Clear all
Active, not recruiting Phase 2 Interventional Results available

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

NCT04225039
View directory record Official record
Conditions
Glioblastoma
Interventions
INCMGA00012, INCAGN01876, SRS, Brain surgery
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Recruiting Phase 3 Interventional

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284
View directory record Official record
Conditions
High-risk Muscle Invasive Urothelial Carcinoma
Interventions
Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions
Durvalumab, External Beam Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

NCT04916002
View directory record Official record
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
Interventions
vidutolimod, cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

NCT04009681
View directory record Official record
Conditions
Metastasis
Interventions
THOR-707, Checkpoint inhibitor, anti-EGFR antibody
Drug
Lead sponsor
Synthorx, Inc, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 21, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT03219333
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions
Enfortumab vedotin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
54
States / cities
Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 1 Interventional

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT04551885
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 21, 2026, 1:16 AM EDT
Withdrawn Phase 2 Interventional

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

NCT04044209
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions
AG-120, Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ADA-011, PD(L)-1 inhibitor
Drug
Lead sponsor
Adanate, Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Scottsdale, Arizona • Orlando, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

NCT03311334
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions
DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

NCT03906526
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
VTX-2337, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 21, 2026, 1:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

NCT07043608
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
Interventions
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan
Drug · Radiation · Procedure
Lead sponsor
Kelly Fitzgerald, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379
View directory record Official record
Conditions
Solid Tumor, Unresectable or Metastatic Melanoma
Interventions
CX-072, Ipilimumab
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 21, 2026, 1:16 AM EDT
Not yet recruiting Phase 2 Interventional

Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status

NCT07796126
View directory record Official record
Conditions
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Interventions
Toripalimab, Paclitaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

NCT03790488
View directory record Official record
Conditions
Cancer
Interventions
JTX-4014
Drug
Lead sponsor
Jounce Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 21, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

NCT03644550
View directory record Official record
Conditions
Mesothelioma
Interventions
LMB-100, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 21, 2026, 1:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

NCT05200559
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Pembrolizumab, E7777
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Enrolling by invitation No phase listed Observational

Development and Analysis of a Stool Bank for Cancer Patients

NCT04291755
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Interventions
Pembrolizumab Injection
Drug
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Fountain Valley, California • Winter Haven, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

NCT04745949
View directory record Official record
Conditions
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

NCT06807593
View directory record Official record
Conditions
Cancer
Interventions
Ustekinumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Withdrawn No phase listed Observational

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

NCT06283238
View directory record Official record
Conditions
GastroEsophageal Cancer
Interventions
Immune checkpoint inhibitor (ICI) or chemotherapy alone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 21, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

NCT02979977
View directory record Official record
Conditions
Squamous Cell Cancers of the Head and Neck
Interventions
cetuximab, afatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 21, 2026, 1:16 AM EDT